QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
NYSE:GKOS

Glaukos - GKOS Stock Forecast, Price & News

$48.28
+0.24 (+0.50%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$47.37
$48.77
50-Day Range
$40.82
$49.21
52-Week Range
$33.33
$64.49
Volume
400,059 shs
Average Volume
361,293 shs
Market Capitalization
$2.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.67

Glaukos MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
17.4% Upside
$56.67 Price Target
Short Interest
Bearish
9.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
0.40mentions of Glaukos in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.23) to ($1.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

764th out of 1,049 stocks

Surgical & Medical Instruments Industry

76th out of 105 stocks


GKOS stock logo

About Glaukos (NYSE:GKOS) Stock

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.

Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Stock News Headlines

Brokerages Set Glaukos Co. (NYSE:GKOS) Price Target at $56.67
Glaukos (NYSE:GKOS) Rating Lowered to Sell at StockNews.com
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Glaukos Co. (NYSE:GKOS) Short Interest Up 5.3% in December
Contrasting Biotricity (OTCMKTS:BTCY) and Glaukos (NYSE:GKOS)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio
Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View
See More Headlines
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Company Calendar

Last Earnings
11/02/2022
Today
1/30/2023
Next Earnings (Estimated)
2/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
727
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$56.67
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$42.00
Forecasted Upside/Downside
+17.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-49,590,000.00
Pretax Margin
-31.42%

Debt

Sales & Book Value

Annual Sales
$294.01 million
Book Value
$12.52 per share

Miscellaneous

Free Float
43,839,000
Market Cap
$2.30 billion
Optionable
Optionable
Beta
1.23

Key Executives

  • Thomas William Burns
    Chairman & Chief Executive Officer
  • Joseph E. GilliamJoseph E. Gilliam
    President & Chief Operating Officer
  • Alex Thurman
    Chief Financial Officer & Senior Vice President
  • Jay L. Katz
    Chief Medical Officer
  • Diane W. Biagianti
    Senior Vice President & General Counsel













GKOS Stock - Frequently Asked Questions

Should I buy or sell Glaukos stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GKOS shares.
View GKOS analyst ratings
or view top-rated stocks.

What is Glaukos' stock price forecast for 2023?

9 Wall Street analysts have issued 1-year price targets for Glaukos' stock. Their GKOS share price forecasts range from $42.00 to $68.00. On average, they anticipate the company's stock price to reach $56.67 in the next twelve months. This suggests a possible upside of 17.8% from the stock's current price.
View analysts price targets for GKOS
or view top-rated stocks among Wall Street analysts.

How have GKOS shares performed in 2023?

Glaukos' stock was trading at $43.68 at the start of the year. Since then, GKOS shares have increased by 10.1% and is now trading at $48.11.
View the best growth stocks for 2023 here
.

Are investors shorting Glaukos?

Glaukos saw a increase in short interest during the month of December. As of December 30th, there was short interest totaling 4,370,000 shares, an increase of 5.3% from the December 15th total of 4,150,000 shares. Based on an average daily volume of 385,500 shares, the days-to-cover ratio is presently 11.3 days. Approximately 9.6% of the company's stock are short sold.
View Glaukos' Short Interest
.

When is Glaukos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our GKOS earnings forecast
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) announced its earnings results on Wednesday, November, 2nd. The medical instruments supplier reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.08. The medical instruments supplier had revenue of $71.27 million for the quarter, compared to analyst estimates of $67.88 million. Glaukos had a negative net margin of 31.45% and a negative trailing twelve-month return on equity of 16.16%.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $278.00 million-$280.00 million, compared to the consensus revenue estimate of $278.63 million.

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Who are Glaukos' major shareholders?

Glaukos' stock is owned by many different retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (1.26%), Peregrine Capital Management LLC (0.24%), Assenagon Asset Management S.A. (0.12%), State of Alaska Department of Revenue (0.07%), Yousif Capital Management LLC (0.06%) and Exchange Traded Concepts LLC (0.06%). Insiders that own company stock include Gilbert H Kliman, Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends
.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $48.11.

How much money does Glaukos make?

Glaukos (NYSE:GKOS) has a market capitalization of $2.29 billion and generates $294.01 million in revenue each year. The medical instruments supplier earns $-49,590,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.

How many employees does Glaukos have?

The company employs 727 workers across the globe.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.

This page (NYSE:GKOS) was last updated on 1/30/2023 by MarketBeat.com Staff